An experimental study to evaluate the effect of memantine in animal models of anxiety in swiss albino mice

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 8, 2015, Pages FF01-FF05

  Bagewadi, Harish G ^a   Afzal Khan, A K ^a   Shivaramegowda, Rekha M ^a  

^a MVJ Medical College and Research Hospital   (India)

Author keywords

Anti anxiety; Lorazepam; Open field test; Passive avoidance test

Indexed keywords

LORAZEPAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY ASSESSMENT; ANXIETY DISORDER; ARTICLE; BEHAVIOR ASSESSMENT; CONDITIONED REFLEX; CONTROLLED STUDY; EXPERIMENTAL STUDY; MOUSE; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE TEST; SENSITIVITY AND SPECIFICITY; TRANQUILIZING ACTIVITY;

ANIMALIA; MUS;

EID: 84938582244     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/13233.6287     Document Type: Article

References (50)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-- R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51(1):8-19.
2. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. Neuro Rx. 2006;3:(1):57-68.
3. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawins JN, Bannerman DM. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol. 2010;626:(1):49-56.
4. Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behaviour in two models of anxiety. Eur Neuropsychopharmacol. 1996;6:(1):55-61.
5. Poleszak E, Serefko A, Szopa A, Wosko S, Dudka J, Wrobel A, et al. NMDA receptor activation antagonizes the NMDA antagonist-induced antianxiety effect in the elevated plus-maze test in mice. Pharmacol Rep. 2013;65(5):1124-31.
6. Lipton SA, Chen HS. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2004;11:18-20.
7. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Neuro Rx. 2004;1:(1):101-10.
8. Martin P, Carlsson M. Systemic PCP treatment elevates brain extracellular 5-HT: a micro dialysis study in awake rats. Neuroreport. 1998;9:(13):2985.
9. Sharma AC, Kulkarni SK. MK-801 produces antianxiety effect in elevated plus- maze in mice. Drug development research. 1991;22;(3):251-58.
10. Shuijin He, Bausch SB.: Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in anin vitro model of limbic epileptogenesis. Neuropharmacology. 2014;77:379-86.
11. Molchanov ML, Guimaraes FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology (Berl). 2002;160:30-38.
12. Criswell HE, Knapp DJ, Overstreet DH, Breese GR. Effects of ethanol, chlordiazepoxide, and MK-801 on performance in the elevated-plus maze and on locomotor activity. Alcohol Clin Exp Res.1994;18:596-601.
13. Kotlinska J, Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology BerlJ.1998;135(2):175-81.
14. Bagewadi HG, Nayaka SR, Venkatadri TV Effect of memantine in experimental models of depression in swiss albino mice. J Chem Pharm Res. 2014;6(12):880-84.
15. Bagewadi HG, Venkatadri TV, Rajeshwari B. To investigate the role of memantine as anxiolytic in elevated plus maze test and as antidepressant in tail suspension test in Swiss albino mice. Int J Basic Clin Pharmacol. 2015;4(2):213-88.
16. Rodgers RJ. Animal models of anxiety. Where next? Behav Phamacol.1997;8:477-96.
17. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviours: A review. European Journal of Pharmacology. 2003;463(1-3):3-33.
18. Boyce-Rustay JM. Holmes A. Genetic Inactivation of the NMDA Receptor NR2A Subunit has Anxiolytic- and Antidepressant-Like Effects in Mice. Neuropsychopharmacology. 2006;31(11):2405-14.
19. Tomilenko RA, Dubrovina NI. Effects of activation and blockade of NMDA receptors on the extinction of a conditioned passive avoidance response in mice with different levels of anxiety. Neurosci Behav Physiol. 2007;37(5):509-15.
20. Grzeda E, Wisniewska RJ, Wi niewski K.Effect of an NMDA receptor agonist on T-maze and passive avoidance test in 12-week streptozotocin-induced diabetic rats. Pharmacol Rep. 2007;59(6):656-63.
21. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP Neuropharmacology. 1997;36(7):961-71.
22. Venable N, Kelly PH. Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology (Berl). 1990;100(2):215-21.
23. Bullock S, Rose SP, Pearce B, Potter J. Training chicks on a passive avoidance task modulates glutamate-stimulated inositol phosphate accumulation. Eur J Neurosci. 1993;5(1):43-48.
24. Wi niewski K, Fedosiewicz-Wasiluk M, Holy ZZ, Car H, Grzeda E. Influence of NMDA, a potent agonist of glutamate receptors, on behavioural activity in 4-week streptozotocin-induced diabetic rats. Pol J Pharmacol. 2003;55(3):345-51.
25. Plaznik A, Palejko W, Nazar M, Jessa M.Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol. 1994;4(4):503-12.
26. Salunke BP Umathe SN, Jagatpalsingh G.: Chavan. Involvement of NMDA receptor in low-frequency magnetic field-induced anxiety in mice. Electromagnetic Biology and Medicine. 2014;33(4):312-26.
27. An XL, Tai FD. Effects of estradiol and clomiphene citrate on behaviour of BALB/cJ mice. Journal of Shaanxi Normal University: Natural Science Edition. 2010;38:(5):82-86.
28. Glotzbach E, Ewald H, Andreatta M, Pauli P, Muhlberger A. Contextual fear conditioning predicts subsequent avoidance behaviour in a virtual reality environment. Cognition and Emotion. 2012;26(7):1256-72.
29. Blanchard RJ, Blanchard DC. Attack and defense in rodents as ethoexperimental models for the study of emotion. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1989;13:S3-14.
30. Blanchard RJ, Griebel G, Henrie JA, Blanchard DC. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev. 1997;21(6):783-89.
31. Blanchard DC, Griebel G, Blanchard RJ. The mouse defensive test battery: Pharmacological and behavioural assays for anxiety and panic. Eur J Pharmacol. 2003;463(1-3):97-116.
32. Cryan JF, Holmes A. The ascent of mouse: Advances in modeling human depression and anxiety. Nature Reviews: Drug Discovery. 2005;4(9):775-90.
33. Hall CS. Emotional behaviour in the rat. I. Defecation and urination as measures of individual differences in emotionality. Journal of Comparative Psychology. 1934;18(3):385-403.
34. Rodgers RJ, Cao BJ, Dalvi A, Holmes A. Animal models of anxiety: An ethological perspective. Brazilian Journal of Medical and Biological Research. 1997;30(3):289-304.
35. Sufka KJ, Warnick JE, Pulaski CN, Slauson SR, Kim YB, Rimoldi JM. Antidepressant efficacy screening of novel targets in the chick anxiety-depression model. Behav Pharmacol. 2009;20(2):146-54.
36. Fredriksson A, Danysz W, Quack G, Archer T Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice. J Neural Transm. 2001;108(2):167-87.
37. Sathyanathan V, Eswar Kumar A, M Suresh Babu, rizwana I, Fatima F. Sedative- hypnotic activity on whole plant extract of Vernonia cinerea (linn.) less. Int J of Res in Pharmacology & Pharmacotherapeutics. 2012;1(2):169-71.
38. Sharma AC, Kulkarni SK. Evidence for GABA-BZ receptor modulation in short term memory passive avoidance task paradigm in mice. Met Find Exp Clin Pharmacol. 1990;12(3):175-80.
39. Sethi A, Das BP, Bajaj BK. The Anxiolytic Activity of Gabapentin in Mice. The Journal of Applied Research. 2005;5(3):415-22.
40. Mattila-Evenden M, Bergman U, Franck J. A study of benzodiazepine users claiming drug-induced psychiatric morbidity. Nord J Psychiatry. 2001;55(4):271-78
41. Erreger K, Chen PE, Wyllie DJ, Traynelis SF. Glutamate receptor gating. Grit Rev Neurobioi. 2004;16(3):187-224.
42. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawins JN, Bannerman DM. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion, Eur J Pharmacol. 2010;626(1):49-56.
43. Martinez G, Ropero C, Funes A, Flores E, Blotta C, Landa AI, Gargiulo PA. Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. Physiol Behav. 2002;76:219-224.
44. Guimaraes FS, Carobrez AP, De Aguiar JC, Graeff FG. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology (Berl). 1991;103(1):91-94.
45. Chisari M, Zorumski CF, Mennerick S. Cross talk between synaptic receptors mediates NMDA-induced suppression of inhibition. J Neurophysiol. 2012;107(9):2532-40.
46. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by Bupropion, Phencyclidine and Ibogaine. J Pharmacol Exp Ther. 1999;288(1):88-92.
47. Wiley JL, Cristello AF, Balster RL. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol. 1995;294:101-107.
48. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, et al. Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12(11):4427-36.
49. Olney JW, Wozniak DF, Faber NB. Glutamate receptor dysfunction and Alzheimer's disease. Restorative Neurology and Neuroscience. 1998;13(1-2):75-83.
50. Wieronska JM, Branski P, Paivcha A, Smiaiowska M. The effect of competitive and non- competitive NMDA receptor antagonists, ACPC and MK-801 on NPY and CRF-like immune reactivity in the rat brain amygdala. Neuropeptides. 2001;35(5-6):219-26